{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:49:13Z","timestamp":1788580153526,"version":"build-2803163510"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["J. Pharm. Pharm. Sci."],"abstract":"<jats:p>\n                    In paediatric wards, bisoprolol, betaxolol, or nadolol can be administered orally at non-licensed dosages. To provide paediatric patients with appropriate treatment, batches of beta-blocker oral suspensions must be compounded, which involves subsequent stability studies. A stability-indicating HPLC-UV method and microbiological analyses were validated. Experimental batches were compounded (betaxolol hydrochloride 1\u00a0mg.mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    , bisoprolol hemifumarate 0.5\u00a0mg.mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    and nadolol 10\u00a0mg.mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    ). Bisoprolol hemifumarate 0.5\u00a0mg.mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    and nadolol 10\u00a0mg.mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    needed the addition of citric acid (3\u00a0mg.mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    ) and potassium sorbate (3\u00a0mg.mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    ) to ensure preservative efficacy. Betaxolol hydrochloride 1\u00a0mg.mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    was stable for 2 months when stored at 2\u20138\u00a0\u00a0\u00b0C, for 1 month after opening at 2\u20138\u00a0\u00b0C, and for 15 days when stored at 25\u00a0\u00b0C\/60% RH. Bisoprolol hemifumarate 0.5\u00a0mg.mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    was stable for 2 months when stored at 2\u20138\u00a0\u00b0C, for 1 month after opening at 2\u20138\u00a0\u00b0C, and for 15 days when stored at 25\u00a0\u00b0C\/60% RH. Nadolol 10\u00a0mg.mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    was stable for 3 months when stored at 2\u20138\u00a0\u00b0C, for 1 month after opening at 2\u20138\u00a0\u00b0C, and for 15 days when stored at 25\u00a0\u00b0C\/60% RH. Hospital pharmacies can compound batches of beta-blocker liquid oral suspensions and store them for secure dispensing and administration.\n                  <\/jats:p>","DOI":"10.3389\/jpps.2025.15387","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:10:24Z","timestamp":1764655824000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Compounding and stability studies of liquid oral formulations of beta-blockers (bisoprolol, betaxolol, and nadolol) for paediatric patients"],"prefix":"10.3389","volume":"28","author":[{"given":"Laura","family":"Dubois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Bouguergour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Paoli-Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Castera-Ducros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Vanelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Rathelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Terme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1136\/adc.59.7.670","article-title":"Betaxolol and propranolol in glucagon stimulation of growth hormone","volume":"59","author":"Colle","year":"1984","journal-title":"Arch Dis Child"},{"key":"B2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1515\/jpem-2021-0045","article-title":"Provocative growth hormone testing in children: how did we get here and where do we go now?","volume":"34","author":"Kamoun","year":"2021","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40272-022-00524-z","article-title":"Can paediatric heart failure therapy be improved? Yes it can, but","volume":"24","author":"Schranz","year":"2022","journal-title":"Pediatr Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.21037\/tp.2019.04.08","article-title":"Paediatric heart failure therapy: why \u03b21-receptor blocker, tissue ACE-I and mineralocorticoid-receptor-blocker?","volume":"8","author":"Recla","year":"2019","journal-title":"Transl Pediatr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/archdischild-2023-NPPG.9","article-title":"Initiation of bisoprolol in paediatric patients - experience from a specialist paediatric cardiac centre","volume":"108","author":"Bueno Gomez","year":"2023","journal-title":"Arch Dis Child"},{"key":"B6","article-title":"Nadolol","volume-title":"StatPearls","author":"Gopal","year":"2025"},{"key":"B7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.healthpol.2014.07.010","article-title":"Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe","volume":"117","author":"Minghetti","year":"2014","journal-title":"Health Policy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/ejhpharm-2012-000194","article-title":"GMP and preparation in hospital pharmacies","volume":"19","author":"Bouwman","year":"2012","journal-title":"Eur J Hosp Pharm"},{"key":"B9","doi-asserted-by":"publisher","first-page":"A58.1","DOI":"10.1136\/ejhpharm-2013-000276.161","article-title":"GRP\u2212161 risk assessment forms for pharmacy preparation","volume":"20","author":"Bouwman","year":"2013","journal-title":"Eur J Hosp Pharm"},{"key":"B10","first-page":"481","article-title":"Introduction to quality control in a compounding pharmacy","volume":"20","author":"Allen","year":"2016","journal-title":"Int J Pharm Compd"},{"key":"B11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.5863\/1551-6776-27.7.625","article-title":"Pre-formulation and stability study of 20-mcg clonidine hydrochloride pediatric capsules","volume":"27","author":"Wasilewski","year":"2022","journal-title":"The J Pediatr Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1691\/ph.2017.7089","article-title":"Stability studies of five anti-infectious eye drops under exhaustive storage conditions","volume":"72","author":"Curti","year":"2017","journal-title":"Pharmazie"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0282164","DOI":"10.1371\/journal.pone.0282164","article-title":"Low-dose erythromycin in pediatrics: formulation and stability of 20 mg hard gelatin capsules","volume":"18","author":"Thevin","year":"2023","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/87551225211015566","article-title":"Beyond-use dates assignment for pharmaceutical preparations: example of low-dose amiodarone capsules","volume":"37","author":"Brun","year":"2021","journal-title":"J Pharm Technology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s0021-9673(02)01536-4","article-title":"Validation of high-performance liquid chromatography methods for pharmaceutical analysis","volume":"987","author":"Shabir","year":"2003","journal-title":"J Chromatogr A"},{"key":"B16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/pharmaceutics15030755","article-title":"Development and stability of a new formulation of pentobarbital suppositories for paediatric procedural sedation","volume":"15","author":"Lebrat","year":"2023","journal-title":"Pharmaceutics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"114543","DOI":"10.1016\/j.jpba.2021.114543","article-title":"Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization","volume":"210","author":"Bourcier","year":"2022","journal-title":"J Pharm Biomed Anal"},{"key":"B18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3390\/ph17060691","article-title":"Formulation and stability of a 1% clarithromycin-based topical skin cream: a new option to treat buruli ulcers?","volume":"17","author":"Sebti","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/10781552231170583","article-title":"Extended physicochemical stability of cetuximab in opened vials and infusion bags when stored at 4 \u00b0C and 25 \u00b0C","volume":"30","author":"Vieillard","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"B20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.18176\/jiaci.0864","article-title":"Stability over time of in-hospital-compounded amoxicillin capsules and ceftriaxone patch tests for drug allergy testing","volume":"33","author":"Gond\u00e9","year":"2023","journal-title":"J Investig Allergy Clin Immunol"},{"key":"B21","article-title":"European pharmacopoeia (11.0). 2.6.12. Microbiological examination of non-sterile products: microbial enumeration tests","year":"2025"},{"key":"B22","article-title":"European pharmacopoeia (11.0). 5.1.3. efficacy of antimicrobial preservation","year":"2025"},{"key":"B23","unstructured":"Impurities in new drug products - scientific guideline\n          \n          \n          2025"},{"key":"B24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","article-title":"Development of forced degradation and stability indicating studies of drugs-A review","volume":"4","author":"Blessy","year":"2014","journal-title":"J Pharm Anal"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/s0731-7085(02)00047-x","article-title":"Development of validated stability-indicating assay methods--critical review","volume":"28","author":"Bakshi","year":"2002","journal-title":"J Pharm Biomed Anal"},{"key":"B26","doi-asserted-by":"publisher","first-page":"ACI.S11256","DOI":"10.4137\/aci.s11256","article-title":"A rapid stability-indicating RP-HPLC method for the determination of betaxolol hydrochloride in pharmaceutical tablets","volume":"8","author":"Auvity","year":"2013","journal-title":"Anal Chem Insights"},{"key":"B27","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/chromsci\/bmae025","article-title":"LC and LC-MS\/MS studies for the separation and identification of impurities and degradation products of betaxolol","volume":"62","author":"Chmangui","year":"2024","journal-title":"J Chromatogr Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.25258\/ijpqa.14.3.07","article-title":"Characterization of degradation products of bisoprolol by LC-MS and in-silico determination of toxicity and biological activity prediction of its degradation product: a comprehensive approach during drug development","volume":"14","author":"Chandramore","year":"2023","journal-title":"Int J Pharm Qual Assur"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2298\/jsc220204053l","article-title":"Forced degradation studies and structural characterization of related substances of bisoprolol fumarate in finished drug product using LC\u2013UV\u2013MS\/MS","volume":"87","author":"Lazarevska Todevska","year":"2022","journal-title":"J Serb Chem Soc"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s11094-020-02146-6","article-title":"Optimized and validated stability indicating RP-HPLC method for estimation of nadolol","volume":"53","author":"Deshpande","year":"2020","journal-title":"Pharm Chem J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1128\/jb.17.5.363-371.1929","article-title":"Effect of hydrogen ion concentration on the toxicity of sodium benzoate to microorganisms","volume":"17","author":"Cruess","year":"1929","journal-title":"J Bacteriol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/molecules29010022","article-title":"Citric acid: properties, microbial production, and applications in industries","volume":"29","author":"Ksi\u0105\u017cek","year":"2023","journal-title":"Molecules"},{"key":"B33","unstructured":"European chemicals agency (ECHA), citric acid report\n          \n          \n          2025"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3390\/nu14071497","article-title":"Sodium benzoate-harmfulness and potential use in therapies for disorders related to the nervous system: a review","volume":"14","author":"Walczak-Nowicka","year":"2022","journal-title":"Nutrients"},{"key":"B35","doi-asserted-by":"publisher","first-page":"C263","DOI":"10.1111\/j.1750-3841.2010.01536.x","article-title":"Evaluation of accelerated UV and thermal testing for benzene formation in beverages containing benzoate and ascorbic acid","volume":"75","author":"Nyman","year":"2010","journal-title":"J Food Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1021\/jf072479l","article-title":"Survey results of benzene in soft drinks and other beverages by headspace gas chromatography\/mass spectrometry","volume":"56","author":"Nyman","year":"2008","journal-title":"J Agric Food Chem"},{"key":"B37","doi-asserted-by":"publisher","first-page":"12975","DOI":"10.1021\/jf203233s","article-title":"Factors influencing benzene formation from the decarboxylation of benzoate in liquid model systems","volume":"59","author":"Medeiros Vinci","year":"2011","journal-title":"J Agric Food Chem"},{"key":"B38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/pharmaceutics16010119","article-title":"Potentially harmful excipients: state of the art for oral liquid forms used in neonatology and pediatrics units","volume":"16","author":"Bobillot","year":"2024","journal-title":"Pharmaceutics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"108671","DOI":"10.1016\/j.envint.2024.108671","article-title":"Association between parabens exposure and neurodevelopment in children","volume":"188","author":"Tung","year":"2024","journal-title":"Environ Int"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/nu15051154","article-title":"Presence of parabens in different children biological matrices and its relationship with body mass index","volume":"15","author":"Moscoso-Ruiz","year":"2023","journal-title":"Nutrients"},{"key":"B41","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ijpharm.2013.08.078","article-title":"European study of neonatal exposure to excipients: an update","volume":"457","author":"Turner","year":"2013","journal-title":"Int J Pharmaceutics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/pharmaceutics13030387","article-title":"Excipients in the paediatric population: a review","volume":"13","author":"Rouaz","year":"2021","journal-title":"Pharmaceutics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1515\/pthp-2018-0008","article-title":"Development and preparation of oral suspensions for paediatric patients \u2013 a challenge for pharmacists","volume":"3","author":"Bruns","year":"2018","journal-title":"Pharm Technology Hosp Pharm"},{"key":"B44","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. French good compounding practices [in French]\n          \n          \n          2025"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1177\/1060028013503137","article-title":"Stability of betaxolol suspensions in oral syringes and glass bottles","volume":"47","author":"Auvity","year":"2013","journal-title":"Ann Pharmacother"},{"key":"B46","first-page":"163","article-title":"Stability of extemporaneously compounded nadolol 10-mg\/mL suspension in oral mix in glass and plastic bottles and plastic syringes","volume":"25","author":"Walsh","year":"2021","journal-title":"Int J Pharm Compd"},{"key":"B47","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/ejhpharm-2016-000903","article-title":"Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions","volume":"23","author":"Polonini","year":"2016","journal-title":"Eur J Hosp Pharm"}],"container-title":["Journal of Pharmacy &amp; Pharmaceutical Sciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/jpps.2025.15387\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:10:29Z","timestamp":1764655829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/jpps.2025.15387\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":47,"alternative-id":["10.3389\/jpps.2025.15387"],"URL":"https:\/\/doi.org\/10.3389\/jpps.2025.15387","relation":{},"ISSN":["1482-1826"],"issn-type":[{"value":"1482-1826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"article-number":"15387"}}